2024
Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatients
2013
Bile duct involvement portends poor prognosis in resected gallbladder carcinoma.
Eil R, Hansen P, Cassera M, Orloff S, Sheppard B, Diggs B, Billingsley K. Bile duct involvement portends poor prognosis in resected gallbladder carcinoma. Gastrointestinal Cancer Research : GCR 2013, 6: 101-5. PMID: 24147157, PMCID: PMC3782874.Peer-Reviewed Original ResearchDisease-specific survivalDisease-free survivalBile duct involvementGallbladder cancerDuct involvementMedian disease-free survivalResection of GBCResectable gallbladder cancerSubset of patientsLog-rank analysisAdjuvant therapyLN involvementPrognostic factorsCox regressionPoor prognosisRetrospective studyUnfavorable prognosisUnivariate analysisGallbladder carcinomaUnivariate associationsStudy populationHigh riskIntraoperative methodHigh mortalityMultivariate analysis
2011
A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma
Bicquart C, Youssef R, Wissel A, Sheppard B, Billingsley K, Thomas C, Wang S. A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s561. DOI: 10.1016/j.ijrobp.2011.06.887.Peer-Reviewed Original Research
2010
Adjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model
2009
A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?
Enestvedt C, Diggs B, Shipley D, Thomas C, Billingsley K. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointestinal Cancer Research : GCR 2009, 3: 233-8. PMID: 21151426, PMCID: PMC3000069.Peer-Reviewed Original ResearchReceipt of chemoradiotherapyAdjuvant therapyAdjuvant chemoradiotherapyIndependent predictorsGastric adenocarcinomaGastric cancerResectable gastric adenocarcinomaModest survival benefitAmerican Joint CommitteeCurrent practice patternsState Cancer RegistryStandard of carePopulation-based analysisAnalysis of survivalGastric cancer treatmentChi-square testBinary logistic regressionEligible patientsN2 diseaseTreatment eraResection typeSurvival benefitLymph nodesAJCC stageCancer Registry
2008
Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
Morris A, Billingsley K, Hayanga A, Matthews B, Baldwin L, Birkmeyer J. Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer. Journal Of The National Cancer Institute 2008, 100: 1740-1740. PMID: 18477800, PMCID: PMC2766763, DOI: 10.1093/jnci/djn396.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantConfidence IntervalsDecision MakingFemaleHealth Services AccessibilityHealthcare DisparitiesHumansLogistic ModelsMaleMedical OncologyMedical Record LinkageMedicareNeoplasm StagingPractice Patterns, Physicians'Radiation OncologyRadiotherapy, AdjuvantRectal NeoplasmsReferral and ConsultationSEER ProgramUnited StatesWhite PeopleConceptsRectal cancerAdjuvant therapyBlack patientsWhite patientsRadiation oncologistsAdjuvant treatmentMedical oncologistsEnd Results-Medicare dataProvider decision makingPatient-provider interactionsFrequency of consultationsLow treatment ratesClinical characteristicsElderly patientsConsultation ratesOncology referralTreatment disparitiesPatient preferencesProvider characteristicsRadiation therapyPatientsOncologistsTherapyStage IITreatment ratesSurvival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Dobie S, Warren J, Matthews B, Schwartz D, Baldwin L, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112: 789-799. PMID: 18189291, PMCID: PMC3103394, DOI: 10.1002/cncr.23244.Peer-Reviewed Original ResearchConceptsStage II patientsRectal cancer patientsStage III patientsII patientsCancer patientsStage IIAdjuvant radiationAdjuvant therapyIII patientsGeneral populationStage II rectal cancer patientsLower cancer-related mortalityReceipt of chemoradiationCancer mortality riskCancer-related mortalityMultivariate logistic regressionAdjusted riskAdjuvant chemoradiationChemotherapy receiptSurgical resectionSurvival benefitSEER-MedicareTherapy adherencePatient groupRadiation therapy
2006
Completion of Therapy by Medicare Patients With Stage III Colon Cancer
Dobie S, Baldwin L, Dominitz J, Matthews B, Billingsley K, Barlow W. Completion of Therapy by Medicare Patients With Stage III Colon Cancer. Journal Of The National Cancer Institute 2006, 98: 610-619. PMID: 16670386, PMCID: PMC3124351, DOI: 10.1093/jnci/djj159.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsFemaleFrail ElderlyHumansLogistic ModelsMaleMedicareNeoplasm StagingPatient CompliancePredictive Value of TestsReproducibility of ResultsRisk FactorsSEER ProgramSocial SupportUnited StatesConceptsStage III colon cancerCompletion of therapyAdjuvant chemotherapyAdjuvant therapyChemotherapy completionPhysician characteristicsMedicare claimsColon cancerStage III colon cancer patientsEnd Results program dataMultivariable logistic regression modelingAdjuvant chemotherapy completionChemotherapy completion rateIncomplete adjuvant chemotherapySEER program dataColon cancer resectionCancer-related mortalityPredictors of initiationColon cancer patientsLogistic regression modelingProgram dataPatient characteristicsCancer resectionTreatment complicationsCancer mortality